Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-1355 (PF 06281355) 是一种有效的 MPO 抑制剂。PF-1355用于血管炎的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 315 | 现货 | ||
2 mg | ¥ 453 | 现货 | ||
5 mg | ¥ 738 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,730 | 现货 | ||
100 mg | ¥ 5,380 | 现货 | ||
200 mg | ¥ 7,380 | 现货 | ||
500 mg | ¥ 10,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 822 | 现货 |
产品描述 | PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases. |
体外活性 | PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) [1]. |
体内活性 | Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment [1]. |
别名 | PF-06281355, PF 06281355, ZINC205721785 |
分子量 | 321.35 |
分子式 | C14H15N3O4S |
CAS No. | 1435467-38-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL (124.5 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.1119 mL | 15.5594 mL | 31.1187 mL | 77.7968 mL |
5 mM | 0.6224 mL | 3.1119 mL | 6.2237 mL | 15.5594 mL | |
10 mM | 0.3112 mL | 1.5559 mL | 3.1119 mL | 7.7797 mL | |
20 mM | 0.1556 mL | 0.778 mL | 1.5559 mL | 3.8898 mL | |
50 mM | 0.0622 mL | 0.3112 mL | 0.6224 mL | 1.5559 mL | |
100 mM | 0.0311 mL | 0.1556 mL | 0.3112 mL | 0.778 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-1355 1435467-38-1 Metabolism Glutathione Peroxidase PF 1355 PF-06281355 PF 06281355 ZINC 205721785 PF1355 PF06281355 ZINC205721785 ZINC-205721785 Inhibitor inhibitor inhibit